Paris–based Primaa, a health tech startup that develops software tools to assist pathologists with cancer and other diagnoses, has raised €2 million from the Fonds Ambition Amorçage Angels or F3A (a fund managed by Bpifrance), Entrepreneurs Investis, 50 Partners, Angels Santé and business angels.
Founded in September of 2018 by siblings Fanny, Stéphane and Marie Sockeel, Primaa has leveraged the latest innovations in AI and deep learning to develop an automated diagnostic software suite for anatomical pathologists. With the new funds, the company plans to accelerate its development and the international marketing of its product.
Primaa develops software tools that assist specialised practitioners by automating sample analysis with the goal of offering an initial diagnosis that is instantaneous, certain and precise. Until now, the process was typically manual: samples were transferred to slides and analysed under the microscope by experts. By digitising the slides and collecting millions of images in a database created with the support of several medical partners, the startup has been able to use AI to identify the various pathologies related to tissue damage and form a diagnosis.
“The software suite helps diagnose the most common pathologies extremely quickly, saving pathologists time and enabling them to respond to the increasing demand for diagnoses,” said Fanny SOCKEEL, CEO of Primaa. “The objective is now to firmly establish Primaa’s suite as the benchmark diagnostic assistance tool for pathology labs, clinics and hospitals worldwide.”
Since its launch, Primaa has built partnerships with several hospitals and laboratories. This field experience represents one of the company’s driving ambitions: to develop the product in close partnership with doctors in order to best fulfill their needs.
The company is now finalising its first tool focused on breast cancer, the most common cancer in women.
Primaa is being deployed in several anatomical pathology departments in France, and several million digital images have already been analysed by the startup. Moving forward, the startup is now working on widening the scope of its offer to other pathologies in the gastrointestinal, urological and dermatological fields.
“We are very proud to participate in this ambitious seed round and support Primaa in its development,” said Bruno Villeneuve, head of investments for Bpifrance’s Fonds Ambition Amorçage Angels. “The project being undertaken by this great, multidisciplinary team has vast potential, bringing artificial intelligence to bear in the service of medical practitioners to assist them in diagnosing cancer. The software solution has been developed in collaboration with renowned institutions and specialists, and great strides have already been made. This funding round will enable the company to accelerate its deployment both in France and internationally.”